TCGA-BL-A3JM-01A-12R-A21D-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 6.73455979
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.610
- G2M_CHECKPOINT+0.520
- MYC_TARGETS_V1+0.490
- MYC_TARGETS_V2+0.480
- UNFOLDED_PROTEIN_RESPONSE+0.360
- WNT_BETA_CATENIN_SIGNALING+0.360
- MITOTIC_SPINDLE+0.310
- DNA_REPAIR+0.260
- MTORC1_SIGNALING+0.170
- HEDGEHOG_SIGNALING+0.160
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.570
- INFLAMMATORY_RESPONSE-0.480
- IL6_JAK_STAT3_SIGNALING-0.400
- COAGULATION-0.390
- HYPOXIA-0.380
- P53_PATHWAY-0.380
- ALLOGRAFT_REJECTION-0.370
- INTERFERON_GAMMA_RESPONSE-0.320
- APOPTOSIS-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_8QB4S4VA | Embryonal tumors | — | 0.931 |
| 2 | BS_5P1TN10Z | Embryonal tumors | — | 0.926 |
| 3 | BS_TV5B86ZD | Embryonal tumors | — | 0.923 |
| 4 | TCGA-78-7155-01A-11R-2039-07 | — | cohortMD1 | 0.920 |
| 5 | SRR13780247 | — | cohortMD1 | 0.916 |
| 6 | ERR2598206 | fetal | fetal | 0.914 |
| 7 | BS_M84H3KXA | medulloblastoma | — | 0.913 |
| 8 | SAMN03290940 | — | — | 0.911 |
| 9 | TCGA-60-2711-01A-01R-0851-07 | — | cohortSQ2 | 0.911 |
| 10 | TCGA-O2-A52S-01A-11R-A262-07 | — | cohortSQ2 | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.610 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |